Association between biomarkers of bone health and osteosarcopenia among Iranian older people: The Bushehr Elderly Health (BEH) program.
Bone turnover markers
Older people
Osteosarcopenia
Journal
BMC geriatrics
ISSN: 1471-2318
Titre abrégé: BMC Geriatr
Pays: England
ID NLM: 100968548
Informations de publication
Date de publication:
19 11 2021
19 11 2021
Historique:
received:
09
05
2021
accepted:
09
11
2021
entrez:
20
11
2021
pubmed:
21
11
2021
medline:
11
1
2022
Statut:
epublish
Résumé
Osteosarcopenia is referred to as co-incidence of osteoporosis/osteopenia and sarcopenia which is defined as a geriatric syndrome with a significant prevalence that increases morbidity and mortality. There are some relevant factors that can show an increased risk of incidence of osteosarcopenia. We aimed to consider the association of bone turnover markers such as Osteocalcin (OC), C-terminal cross-linked telopeptide (CTX), Tartrate Resistant acid Phosphatase (TRAP), Bone Alkaline Phosphatase (BALP) and also other factors like vitamin D, calcium, phosphorous, and ALP with osteosarcopenia in elderly. We carried out a cross-sectional study on a random sample including 400 elder participants of Bushehr Elderly Health (BEH) study, in Iran. Osteopenia/ osteoporosis was defined as a T-score ≤ -1.0 standard deviation below the mean values of a young healthy adult. We defined sarcopenia as low muscle strength (handgrip strength<26 kg for men and <18 kg for women) with reduced skeletal muscle mass [Skeletal muscle index (SMI) < 7.0 kg/m The results showed that there was a statistically significant difference in OC), CTX, TRAP were between the osteosarcopenia (-) and osteosarcopenia (+) groups. No statistically significant difference was observed in BALP, vitamin D, calcium, phosphorous, and ALP between the compared groups. In the multivariable logistic regression model, OC and CTX were associated with increased likelihood of osteosarcopenia [adjusted OR= 1.023(1.002-1.045 for OC, 4.363(1.389-15.474 for CTX)]. Furthermore, TRAP increases the odds of osteosarcopenia in crude model [OR= 1.333 (1.070- 1.660)]. We observed the association between bone turnover markers particularly OC, CTX and osteosarcopenia. Given the rapid growth of the aging population, we should focus on geriatric diseases such as musculoskeletal disorders. Bone turnover markers maybe improve the early diagnosis, screening and assess the response to therapies in people with osteosarcopenia.
Sections du résumé
BACKGROUND
Osteosarcopenia is referred to as co-incidence of osteoporosis/osteopenia and sarcopenia which is defined as a geriatric syndrome with a significant prevalence that increases morbidity and mortality. There are some relevant factors that can show an increased risk of incidence of osteosarcopenia.
AIM
We aimed to consider the association of bone turnover markers such as Osteocalcin (OC), C-terminal cross-linked telopeptide (CTX), Tartrate Resistant acid Phosphatase (TRAP), Bone Alkaline Phosphatase (BALP) and also other factors like vitamin D, calcium, phosphorous, and ALP with osteosarcopenia in elderly.
METHODS
We carried out a cross-sectional study on a random sample including 400 elder participants of Bushehr Elderly Health (BEH) study, in Iran. Osteopenia/ osteoporosis was defined as a T-score ≤ -1.0 standard deviation below the mean values of a young healthy adult. We defined sarcopenia as low muscle strength (handgrip strength<26 kg for men and <18 kg for women) with reduced skeletal muscle mass [Skeletal muscle index (SMI) < 7.0 kg/m
RESULTS
The results showed that there was a statistically significant difference in OC), CTX, TRAP were between the osteosarcopenia (-) and osteosarcopenia (+) groups. No statistically significant difference was observed in BALP, vitamin D, calcium, phosphorous, and ALP between the compared groups. In the multivariable logistic regression model, OC and CTX were associated with increased likelihood of osteosarcopenia [adjusted OR= 1.023(1.002-1.045 for OC, 4.363(1.389-15.474 for CTX)]. Furthermore, TRAP increases the odds of osteosarcopenia in crude model [OR= 1.333 (1.070- 1.660)].
CONCLUSIONS
We observed the association between bone turnover markers particularly OC, CTX and osteosarcopenia. Given the rapid growth of the aging population, we should focus on geriatric diseases such as musculoskeletal disorders. Bone turnover markers maybe improve the early diagnosis, screening and assess the response to therapies in people with osteosarcopenia.
Identifiants
pubmed: 34798818
doi: 10.1186/s12877-021-02608-w
pii: 10.1186/s12877-021-02608-w
pmc: PMC8603566
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
654Informations de copyright
© 2021. The Author(s).
Références
Age Ageing. 2011 Jul;40(4):423-9
pubmed: 21624928
Clin Interv Aging. 2017 Jan 16;12:145-152
pubmed: 28144132
Clin Endocrinol (Oxf). 2016 May;84(5):687-92
pubmed: 26668071
J Clin Diagn Res. 2013 May;7(5):814-6
pubmed: 23814717
J Cell Physiol. 2013 Jun;228(6):1149-53
pubmed: 23139068
Age Ageing. 2010 Jul;39(4):412-23
pubmed: 20392703
Arch Osteoporos. 2021 Jan 21;16(1):16
pubmed: 33475880
J Am Med Dir Assoc. 2015 Apr;16(4):290-5
pubmed: 25512216
J Cachexia Sarcopenia Muscle. 2017 Apr;8(2):259-266
pubmed: 27897409
J Cachexia Sarcopenia Muscle. 2019 Dec;10(6):1228-1240
pubmed: 31225722
Curr Opin Clin Nutr Metab Care. 2017 Nov;20(6):498-503
pubmed: 28806178
World Health Organ Tech Rep Ser. 1994;843:1-129
pubmed: 7941614
J Bone Miner Res. 2009 Apr;24(4):561-74
pubmed: 19257812
Osteoporos Int. 2013 Mar;24(3):1095-100
pubmed: 22535191
Calcif Tissue Int. 2019 Jul;105(1):77-88
pubmed: 30997575
Cardiol Rev. 2005 Nov-Dec;13(6):322-7
pubmed: 16708441
J Cachexia Sarcopenia Muscle. 2018 Feb;9(1):3-19
pubmed: 29151281
BMJ Open. 2017 Aug 4;7(8):e013606
pubmed: 28780537
Biomark Res. 2017 May 18;5:18
pubmed: 28529755
Aging Clin Exp Res. 2016 Oct;28(5):895-9
pubmed: 26563287
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
J Clin Densitom. 2009 Oct-Dec;12(4):413-6
pubmed: 19733110
J Bone Miner Res. 2012 Dec;27(12):2592-602
pubmed: 22836717
Int J Mol Sci. 2020 Nov 17;21(22):
pubmed: 33213099
Clin Chem. 2017 Feb;63(2):464-474
pubmed: 27940448
J Bone Miner Res. 2004 Mar;19(3):386-93
pubmed: 15040826
Best Pract Res Clin Rheumatol. 2017 Apr;31(2):218-242
pubmed: 29224698
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
J Diabetes Metab Disord. 2017 May 16;16:21
pubmed: 28523252
J Bone Miner Res. 1999 Sep;14(9):1614-21
pubmed: 10469291
Cureus. 2021 Mar 11;13(3):e13820
pubmed: 33850676
Arch Osteoporos. 2013;8:136
pubmed: 24113837
BMC Musculoskelet Disord. 2019 Jun 5;20(1):276
pubmed: 31164134
Med Sci Sports Exerc. 2003 Jul;35(7):1196-202
pubmed: 12840642
J Diabetes Metab Disord. 2019 Nov 15;18(2):665-674
pubmed: 31890691
J Diabetes Metab Disord. 2020 May 29;19(2):727-734
pubmed: 33520799
Am J Med. 1993 Jun;94(6):646-50
pubmed: 8506892
Aging Med (Milton). 2019 Sep 08;2(3):147-156
pubmed: 31942528
J Health Popul Nutr. 2011 Apr;29(2):149-55
pubmed: 21608424
Indian J Endocrinol Metab. 2016 Nov-Dec;20(6):846-852
pubmed: 27867890
Calcif Tissue Int. 2020 Apr;106(4):364-370
pubmed: 31848645
J Bone Miner Metab. 2020 Sep;38(5):695-701
pubmed: 32335754
Clin Biochem Rev. 2005 Nov;26(4):97-122
pubmed: 16648882
Front Endocrinol (Lausanne). 2021 May 05;12:669704
pubmed: 34025583
Mol Metab. 2016 Jul 16;5(10):1042-1047
pubmed: 27689017
Int J Prev Med. 2018 Mar 09;9:25
pubmed: 29619149
BMJ Open. 2015 Dec 16;5(12):e009597
pubmed: 26674503
Br J Hosp Med (Lond). 2018 May 2;79(5):253-258
pubmed: 29727228
Bone. 2015 Nov;80:126-130
pubmed: 25886902